Results 1 to 10 of about 1,245 (153)

Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema [PDF]

International Journal of Retina and Vitreous, 2023
Background To assess the efficacy and safety of supra-choroidal (SC) Iluvien in the management of chronic diabetic macular edema (DME). Methods A retrospective interventional non-comparative consecutive case series including patients with chronic DME who
Ehab N. El Rayes, Mahmoud Leila
doaj   +3 more sources

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN^®) for the Treatment of Retinal Conditions. A Review of Clinical Studies. [PDF]

Drug Des Devel Ther, 2023
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non– infectious ...
Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD.   +5 more
europepmc   +4 more sources

Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia [PDF]

Journal of Ophthalmic Inflammation and Infection
Purpose To report the use of Fluocinolone intravitreal implant (Iluvien) for the treatment of persistent cystoid macular edema (CME) due to immune recovery uveitis syndrome in a patient with previous cytomegalovirus retinitis and acute myeloid leukemia ...
JM Cachero Rodríguez, J. Artaraz, Nora Imaz, A. Fonollosa   +3 more
doaj   +3 more sources

Changes in Macular Perfusion After ILUVIEN® Intravitreal Implant for Diabetic Macular Edema: An OCTA Study. [PDF]

Ophthalmol Ther, 2022
The aim of this study was to investigate changes in macular perfusion in patients affected by diabetic macular edema (DME) and treated with ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg using optical coherence tomography angiography ...
Brambati M, Borrelli E, Capone L, Querques L, Sacconi R, Battista M, Bandello F, Querques G.   +7 more
europepmc   +4 more sources

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. [PDF]

Int Ophthalmol, 2023
Purpose: This study assessed the effectiveness of the 0.19-mg fluocinolone acetonide (FAc) implant by multimodal measurements in patients with non-infectious uveitis (NIU) in a real-world setting in Spain.
Moll-Udina A, Hernanz I, Sainz-de-la-Maza M, Pelegrín L, Coelho-Borges AI, Pazos M, Adán A, Llorenç V.   +7 more
europepmc   +4 more sources

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule [PDF]

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of spontaneous anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule.
Manal Alzaabi, Abdel Hakim Taguri, Ahmed Elbarky   +2 more
doaj   +3 more sources

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. [PDF]

Br J Ophthalmol, 2023
Background The ILUVIEN Registry Safety Study was a multicentre, open-label, non-randomised, observational, phase 4 study designed to assess the safety and effectiveness of the fluocinolone acetonide (FAc) implant in all indications in real-world ...
Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L, Bailey C, Chakravarthy U, ILUVIEN Registry Safety Study (IRISS) Investigators Group.   +8 more
europepmc   +2 more sources

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy. [PDF]

Ophthalmol Ther, 2023
Introduction Postoperative cystoid macular edema (PCME) is a complication of several ocular procedures, including pars plana vitrectomy (PPV), due to the activation of the inflammatory cascade.
Lima-Fontes M, Leuzinger-Dias M, Barros-Pereira R, Fernandes V, Falcão M, Falcão-Reis F, Rocha-Sousa A, Alves-Faria P.   +7 more
europepmc   +2 more sources

Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations [PDF]

Clinical Ophthalmology, 2020
Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting ...
Abraldes, M., Adán, A., Armadá, F., Ascaso, F.J., Cabrera, F., Cervera, E., Figueroa, M.S., Pazos, M., Pessoa, B., Reyes, M.Á., Udaondo, P.   +10 more
core   +4 more sources

Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis [PDF]

Indian Journal of Ophthalmology
The management of intermediate and posterior uveitis poses a significant challenge of achieving adequate drug concentrations in the posterior segment over the chronic nature of the disease.
Sarjak M Shah, Priya Prabhu, Jyotirmay Biswas   +2 more
doaj   +2 more sources